Ocugen Inc (OCGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ocugen Inc (OCGN) has a cash flow conversion efficiency ratio of -3.754x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-21.79 Million) by net assets ($5.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Ocugen Inc's balance sheet to measure how much of total assets are equity-financed.
Ocugen Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Ocugen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Ocugen Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Ocugen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ocugen Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dynasty Ceramic Public Company Limited
BK:DCC
|
0.037x |
|
Jiangsu Fasten Co Ltd
SHE:000890
|
0.332x |
|
Deep Industries Limited
NSE:DEEPINDS
|
0.009x |
|
SHELF DRILLING LTD
F:6SD
|
N/A |
|
Jiangxi Synergy Pharmaceutical Co Ltd
SHE:300636
|
0.027x |
|
Anhui Liuguo Chemical Co Ltd
SHG:600470
|
0.226x |
|
Ozak Gayrimenkul Yatirim Ortakligi AS
IS:OZKGY
|
0.000x |
|
Sichuan Shengda Forestry Industry Co Ltd
SHE:002259
|
0.164x |
Annual Cash Flow Conversion Efficiency for Ocugen Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Ocugen Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Ocugen Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-12.17 Million | $-56.96 Million | 4.682x | +429.23% |
| 2024-12-31 | $29.63 Million | $-42.14 Million | -1.422x | +7.03% |
| 2023-12-31 | $40.56 Million | $-62.05 Million | -1.530x | -88.38% |
| 2022-12-31 | $73.98 Million | $-60.08 Million | -0.812x | -62.31% |
| 2021-12-31 | $95.82 Million | $-47.94 Million | -0.500x | +26.70% |
| 2020-12-31 | $21.55 Million | $-14.71 Million | -0.683x | +55.48% |
| 2019-12-31 | $11.02 Million | $-16.89 Million | -1.533x | -104.45% |
| 2018-12-31 | $-458.00K | $-15.78 Million | 34.448x | +1586.17% |
| 2017-12-31 | $-11.27 Million | $-23.02 Million | 2.043x | +207.70% |
| 2016-12-31 | $13.57 Million | $-25.74 Million | -1.897x | -78.10% |
| 2015-12-31 | $28.20 Million | $-30.03 Million | -1.065x | -213.69% |
| 2014-12-31 | $54.21 Million | $-18.41 Million | -0.340x | -267.87% |
| 2013-12-31 | $-75.55 Million | $-15.28 Million | 0.202x | -67.41% |
| 2012-12-31 | $-19.71 Million | $-12.23 Million | 0.621x | -- |
About Ocugen Inc
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase… Read more